# Safety and Tolerability of CHR-2845 to Treat Haematological Diseases or Lymphoid Malignancies

> **NCT00820508** · PHASE1 · COMPLETED · sponsor: **Chroma Therapeutics** · enrollment: 18 (actual)

## Conditions studied

- Hematological Disease
- Lymphoid Malignancies

## Interventions

- **DRUG:** CHR-2845

## Key facts

- **NCT ID:** NCT00820508
- **Lead sponsor:** Chroma Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2011-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00820508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00820508, "Safety and Tolerability of CHR-2845 to Treat Haematological Diseases or Lymphoid Malignancies". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00820508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*